Table 3.
Univariate survival analysis of OS and DFS after allo-HSCT (N = 55).
| Variables | No. of patients | OS | DFS | P | |
|---|---|---|---|---|---|
| Rate/% | P value | Rate/% | P value | ||
| Age | 0.719 | 0.549 | |||
| ≤ 25 | 27 | 14.007 ± 2.052 | 12.263 ± 2.044 | ||
| > 25 | 28 | 18.621 ± 2.625 | 16.713 ± 2.596 | ||
| Sex | 0.906 | 0.591 | |||
| Male | 34 | 17.679 ± 2.380 | 16.791 ± 2.388 | ||
| Female | 21 | 15.2 ± 2.418 | 12.248 ± 2.297 | ||
| Primary disease | 0.187 | 0.296 | |||
| ALL | 23 | 20.761 ± 2.804 | 18.291 ± 2.888 | ||
| AML | 32 | 12.988 ± 1.886 | 11.918 ± 1.829 | ||
| Gene mutation and/or fusion gene | 0.872 | 0.891 | |||
| Yes | 41 | 18.087 ± 2.164 | 15.929 ± 2.16 | ||
| No | 14 | 14.571 ± 2.985 | 13.98 ± 2.886 | ||
| Abnormal chromosome | 0.984 | 0.45 | |||
| Yes | 21 | 14.681 ± 2.369 | 11.695 ± 2.286 | ||
| No | 34 | 17.774 ± 2.366 | 16.922 ± 2.363 | ||
| Disease status at HSCT | 0.433 | 0.392 | |||
| CR1 | 41 | 18.756 ± 2.151 | 17.366 ± 2.163 | ||
| CR2 and CR3 | 6 | 8.767 ± 3.407 | 8.767 ± 3.407 | ||
| NR | 8 | 13.813 ± 3.613 | 10.044 ± 3.128 | ||
| MRD | 0.030 | 0.005 | |||
| Positive | 18 | 10.194 ± 2.318 | 8.069 ± 1.971 | ||
| Negative | 37 | 20.422 ± 2.215 | 18.957 ± 2.246 | ||
| Sex of donor–recipient | 0.585 | 0.649 | |||
| Identical | 42 | 17.467 ± 2.172 | 16.697 ± 2.177 | ||
| Different | 13 | 13.777 ± 2.284 | 9.885 ± 2.145 | ||
| Donor–recipient ABO compatibility | 0.277 | 0.209 | |||
| Compatible | 25 | 12.976 ± 2.148 | 11.272 ± 2.077 | ||
| Incompatible | 30 | 19.607 ± 2.492 | 17.694 ± 2.517 | ||
| Conditioning regimen | 0.406 | 0.872 | |||
| TBI/Cy-based | 36 | 14.072 ± 1.846 | 13.386 ± 1.849 | ||
| Bu/Cy-based | 19 | 19.942 ± 3.119 | 15.622 ± 3.074 | ||
| Donor source | 0.298 | 0.545 | |||
| Haploid donors | 25 | 13.048 ± 2.137 | 12.192 ± 2.11 | ||
| Unrelated donors | 30 | 19.547 ± 2.504 | 16.765 ± 2.515 | ||
| HLA matching | 0.541 | 0.707 | |||
| HLA-match donors | 23 | 16.048 ± 2.303 | 14.388 ± 2.286 | ||
| HLA-mismatched donors | 32 | 16.863 ± 2.443 | 15.1 ± 2.41 | ||
| GVHD prophylaxis | 0.514 | 0.691 | |||
| Control | 14 | 12.914 ± 2.813 | 12.3 ± 2.705 | ||
| Ruxolitinib | 41 | 18.641 ± 2.17 | 16.554 ± 2.178 | ||
| aGVHD | 0.003 | 0.008 | |||
| Yes | 16 | 8.675 ± 2.377 | 8.258 ± 2.225 | ||
| No | 39 | 21.008 ± 2.133 | 18.785 ± 2.207 | ||
| Grade II–IV aGVHD | 0.002 | 0.003 | |||
| Yes | 11 | 7.173 ± 2.575 | 6.718 ± 2.312 | ||
| No | 44 | 20.277 ± 2.040 | 18.307 ± 2.088 | ||
| cGVHD | 0.003 | < 0.001 | |||
| Yes | 16 | 26.9 ± 2.396 | 26.806 ± 2.448 | ||
| No | 39 | 11.967 ± 1.748 | 9.877 ± 1.608 | ||
| Hemorrhagic cystitis | 0.356 | 0.992 | |||
| Yes | 28 | 15.886 ± 2.569 | 15.789 ± 2.585 | ||
| No | 27 | 16.537 ± 2.134 | 13.521 ± 2.111 | ||
| Pulmonary infection | 0.105 | 0.445 | |||
| Yes | 37 | 15.7 ± 2.278 | 14.795 ± 2.262 | ||
| No | 18 | 18.533 ± 2.401 | 14.839 ± 2.573 | ||
| Intestinal infection | 0.703 | 0.41 | |||
| Yes | 16 | 13.125 ± 2.436 | 10.2 ± 2.046 | ||
| No | 39 | 18.503 ± 2.252 | 17.056 ± 2.258 | ||
| EBV infection | 0.282 | 0.205 | |||
| Yes | 4 | 13.25 ± 1.516 | 13.25 ± 1.516 | ||
| No | 51 | 17.286 ± 1.958 | 15.09 ± 1.926 | ||
| CMV infection | 0.279 | 0.193 | |||
| Yes | 43 | 15.986 ± 2.114 | 14.621 ± 2.09 | ||
| No | 12 | 19.1 ± 2.468 | 16.369 ± 2.598 | ||